Article
A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Dec 2006
Thompson Deborah, Seal Sheila, Schutte Mieke, McGuffog Lesley, Barfoot Rita, Renwick Anthony, Eeles Rosalind, Sodha Nayanta, Houlston Richard, Shanley Susan, Klijn Jan, Wasielewski Marijke, Chang-Claude Jenny, Futreal P Andrew, Weber Barbara L, Nathanson Katherine L, Stratton Michael, Meijers-Heijboer Hanne, Rahman Nazneen, Easton Douglas F
Abstract excerpt
The CHEK2 1100delC protein-truncating mutation has a carrier frequency of approximately 0.7% in Northern and Western European populations and confers an approximately 2-fold increased risk of breast cancer. It has also been suggested to increase risks of colorectal and prostate cancer, but its involvement with these or other types of cancer has not been confirmed. The incidence of cancer other than breast cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.